Clinical Trials Logo
  1. Home
  2. Sarcoidosis
  3. NCT02356445
  4. Details
NCT02356445 Clinical Trial

Use of Immunosuppressive Therapy for Sarcoidosis

Sarcoidosis Clinical Trial

Official title:
Outcome of Use of Cytotoxic Drugs for Inflammatory Lung Diseases

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02356445
Other study ID # UCincinnati
Secondary ID
Status Recruiting
Phase N/A
First received November 3, 2014
Last updated August 10, 2017
Start date November 2014
Est. completion date December 2018

Study information
Verified date August 2017
Source University of Cincinnati
Contact Robert P Baughman, MD
Phone 513-584-5225
Email bob.baughman@uc.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Retrospective review of the outcome of use of immunosuppressive drugs in treatment of sarcoidosis

Description:

Patients receiving one or more cytotoxic or other immunosuppressive drug will be observed

Recruitment information / eligibility
Status Recruiting
Enrollment 2000
Est. completion date December 2018
Est. primary completion date November 2018
Accepts healthy volunteers No
Gender All
Age group 15 Years to 90 Years
Eligibility Inclusion Criteria:

Any patient treated for sarcoidosis

Exclusion Criteria:

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Cytotoxic drug
Observe patients versus treatment type

Locations
Country Name City State
United States University of Cincinnati Cincinnati Ohio

Sponsors (1)
Lead Sponsor Collaborator
University of Cincinnati

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Clinical Outcome Number of participants with improvement over two years 2 years
Secondary Toxicity Number of participants with adverse events 2 years
See also
  Status Clinical Trial Phase
Completed NCT04008069 - Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis Phase 2
Recruiting NCT02807025 - Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases N/A
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT00326534 - Rickettsial Genesis to Sarcoidosis in Denmark N/A
Completed NCT00373555 - Endobronchial Ultrasonography in the Diagnosis of Sarcoidosis N/A
Completed NCT00274352 - A Study of Adalimumab to Treat Sarcoidosis of the Skin Phase 2
Recruiting NCT00470327 - A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Completed NCT00512967 - The Occurence of Inflammation and Oxidative Stress in Lung Diseases N/A
Recruiting NCT01745237 - Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
Completed NCT00369980 - Diagnostic Usefulness of Fluorine–18-α–Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis Patient N/A
Completed NCT00366509 - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Completed NCT00379275 - Eye and Immunogenetic Features of Sarcoidosis N/A
Completed NCT06396910 - TB and Sarcoidosis Granuloma
Completed NCT04156789 - Obstructive Sleep Apnoea in Sarcoidosis
Recruiting NCT02916459 - EBUS-TBNA vs Flex 19G EBUS-TBNA N/A
Recruiting NCT02827734 - Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)
Completed NCT02546388 - Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis N/A
Completed NCT01687517 - Efficacy and Safety of Influenza Vaccine During Sarcoidosis Phase 3
Completed NCT01139710 - Sarcoidosis-associated Pulmonary Hypertension N/A
Terminated NCT00747461 - Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Phase 4